You really still have hope for SA? I have come round to Davidal's position that the trial design is hopelessly flawed and the data (if we ever see it) will be useless. With all the patients they have screened, they would have done better to just have a huge n and deal with night-to-night variability in that way.
Couldn't resist taking a tax loss on the COR in my taxable account, but holding on to the other 2/3 of my shares until the bitter end. Might even buy some more.
News 
Market Data 
Discover 
AI
